NCT03185819: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
- State
- Completed
- Phase
- Phase 2
- People
- 147 taking part
- Started
- 5 Oct 2017
- Primary completion
- 31 Mar 2023
- Arms
- Oral Placebo + Esketamine 84 mg, Oral Placebo + Esketamine 56 mg, Oral Placebo + Esketamine 28 mg
- Results
- Posted on the registry
- 14 Jun 2017: Trial registered
- 5 Oct 2017: Trial started
- 31 Mar 2023: Trial completed
- 17 Apr 2024: Trial results posted